Dihydroorotate dehydrogenase

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Lundi, novembre 15, 2021
Photorefractive keratectomy, Wound healing, PK, Safety, DHODH, Argus Panoptes, Private Securities Litigation Reform Act, IgG4-related ophthalmic disease, NASDAQ, CEO, Macular degeneration, Inflammation, Risk, Geographic atrophy, Annual report, Dihydroorotate dehydrogenase, Acquisition, Company, Research, GLOBE, Retinitis pigmentosa, Eye, SEC, Ophthalmology, SALT, Light, Marketing, Patient, Retinal ganglion cell, FDA, Brain, Pharmaceutical industry, Vaccine, Animal

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.

Key Points: 
  • SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.
  • Raised gross proceeds of $10.75 million through a registered direct offering in August to strengthen the companys financial position.
  • Anticipated milestones include:
    Report topline data in fourth quarter of 2021 on a Ph1/2a safety, PK and exploratory ocular surface inflammation (dry eye) trial.
  • Kioras results may also be affected by factors of which Kiora is not currently aware.

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

Retrieved on: 
Lundi, novembre 8, 2021
Photorefractive keratectomy, Wound healing, PK, Safety, DHODH, Private Securities Litigation Reform Act, IgG4-related ophthalmic disease, Investor, NASDAQ, Macular degeneration, Risk, KPRX, Geographic atrophy, CUSIP, Annual report, Dihydroorotate dehydrogenase, GLOBE, Retinitis pigmentosa, Eye, SEC, SALT, Light, Nasdaq, Marketing, Patient, Retinal ganglion cell, FDA, Brain, Pharmaceutical industry

The Companys newly revamped clinical development strategy is available in the Investors section of the Companys new website at www.kiorapharma.com .

Key Points: 
  • The Companys newly revamped clinical development strategy is available in the Investors section of the Companys new website at www.kiorapharma.com .
  • The rebranding reflects our sharpened focus on developing novel ophthalmic therapeutics, said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora.
  • Well continue planned development of our mid and later stage clinical candidates in anterior segment eye diseases and explore partnering opportunities of promising systemic indications outside our core focus.
  • Kioras pipeline now consists of three assets in early to late-stage development for both common and rare eye diseases.

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

Retrieved on: 
Mardi, octobre 26, 2021
MD, Retinitis pigmentosa, Biotechnology, University, Entrepreneurship, Molecular biology, UCLA, MBA, Patient, Private Securities Litigation Reform Act, NASDAQ, Photorefractive keratectomy, UCLA School of Dentistry, Achievement, DHODH, SEC, Eye disease, Geographic atrophy, Brain, Anderson School, Marketing, Dihydroorotate dehydrogenase, Clinical trial, CEO, Light, Berkeley, R, Acquisition, Cornea, Therapy, BS, Risk, GLOBE, UCLA Anderson School of Management, Doctor of Philosophy, HIV disease progression rates, Retina, Ophthalmology, OBG, IgG4-related ophthalmic disease, Pharmaceutical industry

Eric joins EyeGate with a track record for enhancing operational capabilities and a strong background in non-clinical and clinical development of ophthalmology drugs, said Brian M. Strem, PhD, President and Chief Executive Officer of EyeGate.

Key Points: 
  • Eric joins EyeGate with a track record for enhancing operational capabilities and a strong background in non-clinical and clinical development of ophthalmology drugs, said Brian M. Strem, PhD, President and Chief Executive Officer of EyeGate.
  • Further, the Bayon acquisition expands the EyeGate pipeline with an initial opportunity to treat orphan inherited retinal diseases and creates a balanced portfolio of early to mid/late-stage assets and market size opportunities.
  • Prior to joining EyeGate, he served as the CEO of OccuRx Pty Ltd as well as Co-Founder and Director of Bayon, both focused on the development of novel ophthalmic therapeutics.
  • Under the terms of the definitive agreement, EyeGate acquired all of the outstanding shares of Bayon, and Bayon became a wholly owned subsidiary of EyeGate.

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Jeudi, septembre 9, 2021

The presentation will be available on-demand through the H.C. Wainwright conference portal , starting at 7:00 a.m.

Key Points: 
  • The presentation will be available on-demand through the H.C. Wainwright conference portal , starting at 7:00 a.m.
  • EyeGate is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases.
  • EyeGates results may also be affected by factors of which EyeGate is not currently aware.
  • The forward-looking statements in this press release speak only as of the date of this press release.

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Retrieved on: 
Mercredi, septembre 8, 2021

WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) --  EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept (“POC”) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications.

Key Points: 
  • PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (DHODH) and is first-in-class for ophthalmology indications.
  • The randomized, double-masked, placebo-controlled POC study conducted at a site in Vienna, Austria is designed to evaluate the safety, tolerability, and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease.
  • In this study, a total of 21 patients are treated for 12 days with 0.15% of PP-001 or placebo.
  • In addition, EyeGate is developing Ocular Bandage Gel (OBG), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Jeudi, août 12, 2021
Income, Argus Panoptes, NASDAQ, Degenerative disease, DED, Paycheck Protection Program, Letter, Drug development, Research, Company, Private Securities Litigation Reform Act, Common stock, Duane syndrome, GLOBE, Forgiveness, SEC, Ophthalmology, Acquisition, Epithelium, Marketing, Medicare Part D, Cornea, Patient, Â, Growth, Medicare, Conjunctivitis, DHODH, Dihydroorotate dehydrogenase, Risk, OBG, Regenerative medicine, Eye, Pharmaceutical industry, Medical device, Management, Tutoring

In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth, said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate.

Key Points: 
  • In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth, said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate.
  • Report top-line data from the proof-of-concept study in Austria for patients with DED in Q4 2021.
  • During the second quarter of 2021, the Company recorded a gain of $0.278 million due to the full forgiveness of loan funds received under the Paycheck Protection Program.
  • EyeGates results may also be affected by factors of which EyeGate is not currently aware.

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Mercredi, août 11, 2021
Acquisition, Eye, File, Sale, NASDAQ, Patient, Drug Master File, OBG, SEC, Duane syndrome, Act, Risk, Cornea, DHODH, 3rd Floor, GLOBE, Company, Private Securities Litigation Reform Act, Regulation D, Security (finance), U.S. Securities and Exchange Commission, LLC, Research, Marketing, Dihydroorotate dehydrogenase, Conjunctivitis, Park Avenue, Securities Act of 1933, Pharmaceutical industry

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The warrants have an exercise price of $2.24per share, are exercisable immediately upon issuance and will expirefive and one-halfyearsfollowing the date of issuance.
  • EyeGate has not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes.
  • The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the effective registration statement.

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Mardi, août 10, 2021
NASDAQ, OBG, LLC, Private Securities Litigation Reform Act, Duane syndrome, File, DHODH, Patient, Research, Eye, Marketing, Securities Act of 1933, U.S. Securities and Exchange Commission, Act, Conjunctivitis, Cornea, SEC, Acquisition, Dihydroorotate dehydrogenase, Sale, GLOBE, Regulation D, Company, Risk, Drug Master File, Security (finance), Park Avenue, 3rd Floor, Pharmaceutical industry

The closing of the offering is expected to occur on or aboutAugust 11, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or aboutAugust 11, 2021, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The warrants have an exercise price of $2.24per share, are exercisable immediately upon issuance and will expirefive and one-halfyearsfollowing the date of issuance.
  • EyeGate has not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes.

2021 Dihydroorotate Dehydrogenase Inhibitors Pipeline Market Report - ResearchAndMarkets.com

Retrieved on: 
Mardi, juillet 6, 2021
Biotechnology, Pharmaceutical, Health, Dihydroorotate dehydrogenase, Pipeline

The "Dihydroorotate Dehydrogenase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dihydroorotate Dehydrogenase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Dihydroorotate dehydrogenase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate dehydrogenase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Dihydroorotate dehydrogenase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Phase II/III include, Immunic
    Dihydroorotate dehydrogenase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

Retrieved on: 
Mardi, janvier 26, 2021
Medical specialties, Anilides, Immunosuppressants, Sanofi, Functional groups, Chemical compounds, Isoxazoles, Leflunomide, Prodrugs, Dihydroorotate dehydrogenase, Teriflunomide, Hepatotoxicity

Drug-induced liver injury (DILI) is a major driver of both pre- and post-market drug attrition, often hampering the development of therapeutically applicable compounds.

Key Points: 
  • Drug-induced liver injury (DILI) is a major driver of both pre- and post-market drug attrition, often hampering the development of therapeutically applicable compounds.
  • Safety concerns around the use of first generation DHODH inhibitors (leflunomide and teriflunomide) have arisen in recent years and the US Food and Drug Administration has issued black-box warnings for hepatotoxicity.
  • Scientists at the University of Liverpool, a world leading centre for hepatotoxicity, undertook a study to evaluate the hepatotoxic potential of a panel of six DHODH inhibitors in two readily available hepatic in vitro models.
  • The publication, titled Investigating Dihydroorotate Dehydrogenase Inhibitor Mediated Mitochondrial Dysfunction in Hepatic in vitro Models, is available to view at: https://doi.org/10.1016/j.tiv.2021.105096